193 related articles for article (PubMed ID: 38165971)
1. Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study.
Bellini A; Finocchietti M; Rosa AC; Nordio M; Ferroni E; Massari M; Spila Alegiani S; Masiero L; Bedeschi G; Cardillo M; Lucenteforte E; Piccolo G; Leoni O; Pierobon S; Ledda S; Garau D; Davoli M; Addis A; Belleudi V;
PLoS One; 2024; 19(1):e0295205. PubMed ID: 38165971
[TBL] [Abstract][Full Text] [Related]
2. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.
Johnson C; Ahsan N; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; van Veldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2000 Mar; 69(5):834-41. PubMed ID: 10755536
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of immunosuppressive regimens in renal transplantation.
Guerra G; Ciancio G; Gaynor JJ; Zarak A; Brown R; Hanson L; Sageshima J; Roth D; Chen L; Kupin W; Tueros L; Ruiz P; Livingstone AS; Burke GW
J Am Soc Nephrol; 2011 Sep; 22(9):1758-68. PubMed ID: 21807891
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
6. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.
Rodríguez-Perálvarez M; Guerrero-Misas M; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011639. PubMed ID: 28362060
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
8. Impact of different immunosuppressive protocols on clinical outcomes in obese kidney transplant recipients: a propensity score-matched analysis.
Serna-Higuita LM; Della Penna A; Guthoff M; Heyne N; Beer-Hammer S; Nadalin S; Martus P; Königsrainer A; Quante M
Nephrol Dial Transplant; 2023 Aug; 38(9):2052-2066. PubMed ID: 36662032
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients.
Silva HT; Yang HC; Meier-Kriesche HU; Croy R; Holman J; Fitzsimmons WE; First MR
Transplantation; 2014 Mar; 97(6):636-41. PubMed ID: 24521771
[TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
Ekberg H; Bernasconi C; Tedesco-Silva H; Vítko S; Hugo C; Demirbas A; Acevedo RR; Grinyó J; Frei U; Vanrenterghem Y; Daloze P; Halloran P
Am J Transplant; 2009 Aug; 9(8):1876-85. PubMed ID: 19563339
[TBL] [Abstract][Full Text] [Related]
11. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation.
Morales JM
Kidney Int Suppl; 2002 Dec; (82):S81-7. PubMed ID: 12410861
[TBL] [Abstract][Full Text] [Related]
12. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
Miller J; Mendez R; Pirsch JD; Jensik SC
Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years.
Ahsan N; Johnson C; Gonwa T; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Salm K; Tolzman D; Fitzsimmons WE
Transplantation; 2001 Jul; 72(2):245-50. PubMed ID: 11477347
[TBL] [Abstract][Full Text] [Related]
15. Combination of calcineurin and mTOR inhibitors in kidney transplantation: a propensity score analysis based on current clinical practice.
Cucchiari D; Ríos J; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Rovira J; Torres F; Solè M; Campistol JM; Diekmann F; Oppenheimer F
J Nephrol; 2020 Jun; 33(3):601-610. PubMed ID: 31853792
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
17. Calcineurin inhibitors in renal transplantation: what is the best option?
Tanabe K
Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
[TBL] [Abstract][Full Text] [Related]
18. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
19. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
20. Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation.
Vincenti F; Tuncer M; Castagneto M; Klinger M; Friman S; Scheuermann EH; Wiecek A; Russ GR; Martinek A; Nonnast-Daniel B;
Transplant Proc; 2005 Mar; 37(2):1001-4. PubMed ID: 15848604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
